American Journal of Medical Sciences and Medicine
ISSN (Print): 2327-6681 ISSN (Online): 2327-6657 Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Medical Sciences and Medicine. 2019, 7(1), 9-12
DOI: 10.12691/ajmsm-7-1-3
Open AccessArticle

The Effect of Hypermagnesemia on Platelet Aggregation in Peritoneal Dialysis Patients: An in Vitro Study

Serkan Bakirdogen1, , M.Baki Cekmen2, Umit Bilgili3, Ozgur Mehtap4, Necmi Eren5, Sibel Gokcay Bek5, Ferruh Kemal Isman2, Sara Yavuz6, Mehmet Tuncay7 and Coskun Bakar8

1Department of Nephrology, Canakkale Onsekiz Mart University, The School of Medicine, Canakkale, Turkey

2Department of Medical Biochemistry, Medeniyet University, The School of Medicine, Istanbul, Turkey

3Department of Medical Biochemistry, Fatih Sultan Mehmet Educating and Research Hospital, Istanbul, Turkey

4Department of Hematology, Kocaeli University, The School of Medicine, Kocaeli, Turkey

5Department of Nephrology, Kocaeli University, The School of Medicine, Kocaeli, Turkey

6Division of Nephrology, Department of Internal Medicine, Yeditepe University, The School of Medicine, Istanbul, Turkey

7Department of Nephrology, Ersin Arslan Educating and Research Hospital, Gaziantep, Turkey

8Department of Public Health, Canakkale Onsekiz Mart University, The School of Medicine, Canakkale, Turkey

Pub. Date: February 17, 2019

Cite this paper:
Serkan Bakirdogen, M.Baki Cekmen, Umit Bilgili, Ozgur Mehtap, Necmi Eren, Sibel Gokcay Bek, Ferruh Kemal Isman, Sara Yavuz, Mehmet Tuncay and Coskun Bakar. The Effect of Hypermagnesemia on Platelet Aggregation in Peritoneal Dialysis Patients: An in Vitro Study. American Journal of Medical Sciences and Medicine. 2019; 7(1):9-12. doi: 10.12691/ajmsm-7-1-3


Magnesium has a reducing effect on platelet aggregation. Decreased glomerular filtration rate in chronic renal failure contributes to elevation of serum magnesium level. The aim of our study was to measure platelet aggregation in peritoneal dialysis (PD) patients who developed hypermagnesemia by the addition of magnesiun sulphate (MgSO4) in vitro. Forty-three patients with PD were included in the study. Multiple electrode aggregometry method capable of measuring platelet aggregation in whole blood was used and adenosine diphosphate (ADP) was selected as the agonist. Only ADP was used in the first test cell (C1) of the device; ADP was added as a whole blood agonist, which was raised to magnesium level 3-3,5 mg/dl by the addition of in vitro MgSO4 in the second test cell (C2). Three criteria were used to measure platelet aggregation: aggregation, area under the curve (AUC), and velocity. There was a statistically significant positive correlation between C1-C2 AUC and C1-C2 velocitiy. There was no statistically significant relationship between C1-C2 aggregation. PD patients were divided into two groups, male and female, and the results were examined. In male patient group; there was no statistically significant difference between C1-C2 AUC, C1-C2 aggregation and C1-C2 velocity. In the female patient group; there was no statistically significant difference between C1-C2 AUC. There was a statistically significant positive correlation between C1-C2 aggregation and C1-C2 velocities. Serum magnesium levels may be effective on platelet aggregation in female patients with PD but no similar effect was found in male patients.

hypermagnesemia platelet aggregation multiple electrode aggregometry chronic renal failure peritoneal dialysis

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Schuff-Werner, P., Steiner, M., Fenger, S., Gross, H.J., Bierlich, A., Dreissiger, K., Mannuß, S., Siegert, G., Bachem, M., Kohlschein, P, “Effective estimation of correct platelet counts in pseudothrombocytopenia using an alternative anticoagulant based on magnesium salt”, Br J Haematol., 162 (5). 684-92. 2013.
[2]  Euser, A.G., Cipolla, M.J, “Magnesium sulfate for the treatment of eclampsia: a brief review”, Stroke, 40. 1169-75. 2009.
[3]  Atar, D., Serebruany, V., Poulton, J., Godard, J., Schneider, A., Herzog, WR, “Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion”, J Cardiovasc Pharmacol., 24 (4). 603-11. 1994.
[4]  Hwang, D.L., Yen, C.F., Nadler, J.L, “Effect of extra-cellular magnesium on platelet activation and intracellular calcium mobilization”, Am J Hypertens., 5. 700-6. 1992.
[5]  Corsonello, A., Malara, A., De Domenico, D., Damiano, M.C., Mirone, S., Loddo, S., Ientile, R., Corica, F, “Effects of magnesium sulphate on leptin-dependent platelet aggregation: an ex vivo study”, Magnes Res., 18 (1).7-11.2005.
[6]  Rukshin, V., Azarbal, B., Shah, P.K., Tsang, V.T., Shechter, M., Finkelstein, A., Cercek, B, Kaul, S, “Intravenous magnesium in experimental stent thrombosis in swine”, Thromb Vasc Biol., 21. 1544-9. 2001.
[7]  Shechter, M., Merz, C.N.B., Paul-Labrador, M., Meisel, S.R., Rude, R.K., Molloy, M.D., Dwyer, J.H., Shah, P.K., and Kaul, S, “Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease”, Am J Cardiol., 84. 152-6.1999.
[8]  Massry, S.G, “Magnesium homeostasis in patients with renal failure”, Contrib Nephrol., 38. 175-84. 1984.
[9]  Alhosaini, M., Walter, J.S., Singh, S., Dieter, R.S., Hsieh, A., Leehey, D.J, “Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors”, Am J Nephrol, 39. 204-9. 2014.
[10]  Ejaz, A.A., McShane, A.P., Gandhi, V.C., Leehey, D.J, Ing, T.S, “Hypomagnesemia in continuous ambulatory peritoneal dialysis patients dialyzed with a low-magnesium peritoneal dialysis solution”, Perit Dial Int., 15. 61-4. 1995.
[11]  Foley, R.N., Parfrey, P.S, “Cardiovascular disease and mortality in ESRD”, Journal of Nephrology, 11 (5). 239-45. 1998.
[12]  Gawaz, M., Langer, H., May, A.E, “Platelets in inflammation and atherogenesis”, J Clin Invest., 115. 3378-84. 2005.
[13]  Görlinger, K., Jambor, C., Hanke, A.A., Dirkmann, D., Adamzik, M., Hartmann, M., Rahe-Meyer, N, “Perioperative coagulation management and control of platelet transfusion by point-of-care platelet function analysis”, Transfus Med Hemother., 34. 396-411. 2007.
[14]  Tόth, O., Calatzis, A., Penz, S., Losonczy, H., Siess, W, “Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood”, Thromb Haemost., 96 (6).781-8. 2006.
[15]  Hörl, W.H, Other blood and immune disorders in chronic kidney disease, in Comprehensive Clinical Nephrology, Fourth Edition, Floege J, Johnson RJ, Feehally J, St.Louis Missouri, Elsevier Saunders, 2010, 959-68.
[16]  Jana, P., Maiti, S., Kahn, N.N., Sinha, A.K, “Estriol-induced fibrinolysis due to the activation of plasminogen to plasmin by nitric oxide synthesis in platelets”, Blood Coagul Fibrinolysis, 26 (3). 316-23. 2015.
[17]  Chen, L., Liu, Y., Cui, B., Mi, Q., Huang, Y., Fan, L., Chen, Q., Tang, J., Ferro, A., Ji, Y, “17 Beta-oestradiol partially attenuates the inhibition of nitric oxide synthase-3 by advanced glycation end-products in human platelets”, Clin Exp Pharmacol., 34 (10). 972-8. 2007.
[18]  Anwaar, I., Rendell, M., Gottsäter, A., Lindgärde, F., Hulthén, U.L., Mattiasson, I, “Hormone replacement therapy in healthy postmenopausal women. Effects on intraplatelet cyclic guanosine monophosphate, plasma endothelin-1 and neopterin”, J Intern Med., 247 (4). 463-70. 2000.
[19]  Raz, L., Hunter, L.W., Jayachandran, M., Heit, J.A., Miller, V.M, “Differential effects of oral and transdermal menopausal hormone therapy on prostacyclin and thromboxane in platelets”, Physiol Rep., 2(3).e00275. 2014.
[20]  Wu, G.J., Lee, J.J., Chou, D.S., Jayakumar, T., Hsiao, G., Chen, W.F., Sheu, J.R, “Inhibitory signaling of 17 β-estradiol in platelet activation: the pivotal role of cyclic AMP-mediated nitric oxide synthase activation”, Eur J Pharmacol., 649 (1-3). 140-9. 2010.
[21]  Leoncini, G., Bruzzese, D., Signorello, M.G., Armani, U., Piana, A., Ghiglione, D., Camicione, P, “Platelet activation by collagen is increased in retinal vein occlusion”, Thromb Haemost., 97 (2). 218-27. 2007.
[22]  Misra, A., Srivastava, S., Ankireddy, S.R., Islam, N.S., Chandra, T., Kumar, A., Barthwal, M.K., Dikshit, M, “Phospholipase C-γ2 via p38 and ERK1/2 MAK kinase mediates diperoxovanadate-asparagine induced human platelet aggregation and sCD40L release”, Redox Rep., 18 (5). 174-85. 2013.
[23]  Hedges, S.J., Dehoney, S.B., Hooper, J.S., Amanzadeh, J., Busti, A.J, “Evidence-based treatment recommendations for uremic bleeding”, Nat Clin Pract Nephrol., 3 (3). 138-53. 2007.